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Abstract
Background Our aim is to assess whether the poor breast cancer specific survival (BCSS) seen in women with breast cancer 
and impaired renal function can be explained by associations with other prognostic factors.
Methods The study group was a consecutive series of patients undergoing breast ultrasound (US) who had invasive breast 
cancer (n = 1171). All women had their US diameter and mean stiffness (kPa) at shear wave elastography (SWE) recorded. 
The core biopsy grade and receptor status were noted. Core biopsy of abnormal axillary nodes and the patient referral source 
was also noted. Survival including cause of death was ascertained. Comorbidities at diagnosis were recorded. Patients were 
divided into those with a GFR<60 (“renal group”), those with other comorbidities and those with none. BCSS was assessed 
using Kaplan–Meier survival curves and Cox proportional hazards regression.
Results One thousand, one hundred and forty-one patients constituted the study group. 107 (9%) patients had impaired renal 
function, 182 (16%) had other comorbidities while 852 (75%) had no comorbidities. Mean follow-up was 5.8 years. 109 
breast cancer and 122 non-breast cancer deaths occurred. BCSS in the renal group was significantly worse than the other 
groups. Women with renal comorbidity were older, more likely to present symptomatically, have a pre-operative diagnosis 
of axillary metastases, and have larger and stiffer cancers. Cox proportional hazards regression showed that renal impairment 
maintained independent significance.
Conclusion The poor BCSS in women with impaired renal function is partially explained by advanced tumour stage at 
presentation. However, impaired renal function maintains an independent prognostic effect.
Keywords Renal impairment · Breast cancer · Mortality · Prognostic factors
Introduction
Comorbidities are important in breast cancer management as 
many women with breast cancer die from other causes and 
comorbidities impact on treatment options for breast cancer 
patients, particularly the appropriateness of chemotherapy.
There is a linear decline in glomerular filtration rate 
(GFR) from age 30 so that values in octagenarians are only 
half to two-thirds of those measured in young adults [1]. As 
breast cancer incidence increases with age, it is therefore 
common to find older women presenting with breast cancer 
and impaired renal function. While many comorbidities are 
associated with poorer overall survival in women with breast 
cancer [2, 3], a number of studies have found that impaired 
renal function is associated with poorer breast cancer spe-
cific survival [4, 5] while other comorbidities such as diabe-
tes and cerebro-vascular disease are not [5, 6].
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Little attention has previously been paid to correcting 
for known tumour prognostic factors when evaluating the 
impact of comorbidities on breast cancer survival. How-
ever, patients with comorbidities are more likely to receive 
primary or neoadjuvant endocrine therapy and not receive 
immediate surgery, the specimen from which has tradition-
ally been used to assess prognosis. Therefore, traditional 
prognostic information is not available in many women with 
comorbidities. However, recent work has highlighted prog-
nostic indicators which are available pre-operatively on all 
patients. These include tumour core biopsy grade, oestrogen 
(ER) and HER-2 receptor status, ultrasound (US) tumour 
size, pre-operative diagnosis of axillary metastases, patient 
source, (mammographic screening or symptomatic presen-
tation [7]) and lesion stiffness on shear wave elastography 
(SWE) which is an ultrasound technique [8].
The aim of this study is to assess whether the poor prog-
nostic effect of impaired renal function can be explained 
by associations with other known prognostic factors or if 
impaired renal function has independent prognostic sig-
nificance in a prospectively collected consecutive series of 
patients with invasive breast cancer.
Materials and methods
The study group was collected prospectively from a con-
secutive series of patients undergoing diagnostic breast US 
examination for lesions subsequently shown to be invasive 
breast cancer (n = 1171) between April 2010 and September 
2015. All women had their US lesion diameter and mean 
stiffness (kPa) at SWE recorded irrespective of subsequent 
treatment (primary surgery, neoadjuvant systemic therapy 
and primary endocrine therapy). The core biopsy grade was 
recorded and ER status and HER-2 status were measured 
on the core biopsy samples. All women had axillary US 
and core biopsy of abnormal nodes (node cortical thickness 
of > 2.3 mm was considered abnormal) for assessment of 
nodal status. The patient source, (mammographic screening 
or symptomatic presentation) was also recorded.
Patient’s survival including cause of death was ascer-
tained from local paper and electronic health records and 
the National Cancer Registry. Patients who died after devel-
oping metastatic breast cancer were assumed to have died of 
breast cancer. A total of 30 patients were excluded from the 
analysis on the following grounds: metastases at presenta-
tion; cause of death that could not be ascertained and history 
of a previous breast cancer.
Comorbidities included in the Charlson comorbid-
ity index [9] were obtained retrospectively by examining 
the local electronic health records prior to diagnosis. Fac-
tors recorded included a GFR less than 60, diabetes, liver 
failure, previous non-breast invasive cancer (excluding 
non-melanoma skin cancer), lymphoma, multiple sclerosis, 
peripheral vascular disease, stroke/TIA, coronary heart dis-
ease, ulcerative colitis, chronic obstructive pulmonary dis-
ease (COPD), dementia, SLE, peptic ulcer and rheumatoid 
arthritis.
Patients were divided into three groups: those with a 
GFR<60 (renal group), those with other comorbidities and 
those with no comorbidities. If patient had multiple comor-
bidities including reduced renal function, they were included 
in the renal comorbidities group.
The non-breast cancer mortality of the renal comorbidity 
group, the other comorbidity group and the no comorbidity 
group was assessed using Kaplan–Meier survival curves. The 
differences between categorical cancer and patient character-
istics in the renal and other comorbidity groups were assessed 
using the Chi-square and Fisher’s exact test. Continuous char-
acteristics were assessed using a comparison of ROC curves 
using the log-rank test. Kaplan–Meier survival curves were 
also used to compare the BCSS of the renal and other comor-
bidity groups. Cox proportional hazards regression was used 
to assess the independent impact on breast cancer specific 
survival of renal impairment. This analysis included factors 
found to be significant on univariate analysis when compar-
ing the renal and other comorbidity groups and was carried 
out on a combined dataset of both these groups. Statistical 
analyses were performed using Med Calc software.
Results
After the exclusions detailed above, 1141 patients consti-
tuted the study group. 107 (9%) patients had impaired renal 
function, 182 (16%) had other comorbidities with normal 
renal function while 852 (75%) had no comorbidities. Of 
the 107 patients with impaired renal function 45 had other 
comorbidities, most commonly diabetes (n = 21). The 
mean age of patients in the renal, other and no comorbidity 
groups were 75.3 years, 69.0 years and 59.8 years, respec-
tively. Table 1 shows the frequency of comorbidities. The 
Table 1  Frequency of commonest comorbidities
Comorbidity Number (%)
Renal impairment 107 (9%)
Diabetes 70 (6%)
Coronary heart disease 31 (3%)
Other malignancy 30 (3%)
COPD 25 (2%)
Cerebrovascular disease 21 (2%)
Peptic ulcer 19 (2%)
Rheumatoid arthritis 18 (2%)
Dementia 8 (1%)
Peripheral vascular disease 4 (0.4%)
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Comparison of survival curves (Logrank test)
Chi-squared 128.1444
DF 2
Significance P < 0.0001
Hazard ratiosa with 95% Confidence Interval
Factor none other renal
none - 5.24123.1870 to 8.6195
7.8357
4.1045 to 14.9589
other 0.19080.1160 to 0.3138 -
1.4950
0.6966 to 3.2084
renal 0.12760.06685 to 0.2436
0.6689
















849 817 664 321 62 0
Group: other
178 161 136 61 13 0
Group: renal





Fig. 1  Kaplan–Meier survival curves for non-breast cancer deaths according to type and presence of comorbidities
 International Journal of Clinical Oncology
1 3
commonest comorbidities were impaired renal function fol-
lowed by diabetes.
Mean follow-up in those alive at the end of follow-up 
was 5.8 years. One hundred and nine breast cancer and 122 
non-breast cancer deaths occurred in the entire cohort. The 
number of breast cancer and non-breast cancer deaths in the 
renal comorbidity group was 18 and 36, respectively. The 
number of breast cancer and non-breast cancer deaths in the 
other comorbidity group was 11 and 44, respectively.
Figure 1 shows the non-breast cancer mortality for the 
three groups. The non-breast cancer mortality in the two 
comorbidity groups was significantly worse than in the no 
comorbidity group (< 0.0001). However, the non-breast can-
cer mortality was similar in the renal and other comorbidity 
groups.
Figure 2 shows the breast cancer mortality of the indi-
vidual comorbidities. The curves suggest that patients with 
impaired renal function have poorer breast cancer specific 
survival than patients with other individual comorbidities.
Figure 3 shows the breast cancer mortality for the three 
groups. The breast cancer mortality in the renal group was 
significantly worse than either the other comorbidity group 
or the no comorbidity group.
Table 2 shows the breast cancer and patient character-
istics of the two comorbidity groups. Women with renal 
comorbidity were older and more likely to have symptomatic 
cancer than women in the other comorbidity group. Cancers 
in the renal group were more likely to have a pre-operative 
diagnosis of axillary metastases, had larger US sizes, and 
were stiffer on SWE.
The results of Cox proportional hazards regression for 
breast cancer death in the renal comorbidity and other 
comorbidity groups combined are shown in Table 3. The 
analysis included those factors shown to be significant when 
comparing the renal and other comorbidity groups, i.e., age, 
source (symptomatic or screening presentation), ultrasound 
size, stiffness at SWE and pre-operative diagnosis of axil-
lary metastases. The strongest predictor of breast cancer 
death was a preoperative diagnosis of axillary metastases, 
but renal impairment maintains independent significance. 
Ultrasound tumour size and patient source were of border-
line significance.
Discussion
We have shown that that the poorer breast cancer specific 
survival in patients with impaired renal function is related to 
more advanced tumour stage at diagnosis, but that impaired 
renal function is still an independent poor prognostic marker. 
The more advanced stage in these patients may be related 
to the patient’s age, as most are above routine screening age 
and present with symptoms. Breast cancer patients with 
impaired renal function are significantly older than patients 
with other comorbidities. Older patients with comorbidities 
might also be more reluctant to present or present later with 
breast symptoms than younger women with comorbidities.
There have been a number of previous suggestions as to 
why impaired renal function is associated with poor breast 
cancer survival, including that renal impairment leads to 
the development of more aggressive, or more treatment-
resistant disease [10]. This would seem unlikely as the 
histological grade distribution and ER and HER-2 recep-
tor status of patients with renal and other comorbidities are 
similar (Table 2). The suggestion that comorbidity may lead 
to poor organ function, making it difficult to receive optimal 
therapy and therefore suboptimal treatment seems credible. 
Chemotherapy rates were low in both comorbidity groups 
in our study but lowest in the renal group (13% vs 19%). 
Despite a plan to give chemotherapy, poor renal function 
may lead to dose reduction or discontinuation more com-
monly than in women with non-renal comorbidities or with-
out comorbidity. Approximately half of all chemotherapy 
agent are excreted the kidneys, so poor renal function can 
lead to accumulation of toxic metabolites and overdosage 
[11]. Reduced renal function is  also associated with a higher 
risk of developing cardiotoxicity in patients with HER 2 
positive disease being treated with Trastuzumab [12]. It has 
been suggested that erythropoiesis stimulating agents may 
Fig. 2  Breast cancer survival for patients with individual comorbidi-
ties
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Comparison of survival curves (Logrank test)
Chi-squared 10.8155
DF 2
Significance P = 0.0045
Hazard ratiosa with 95% Confidence Interval
Factor none other renal
none - 0.66740.3963 to 1.1240
2.0324
1.0273 to 4.0212
other 1.49830.8897 to 2.5232 -
3.0452
1.3645 to 6.7960
renal 0.49200.2487 to 0.9735
0.3284
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Fig. 3  Kaplan–Meier survival curves for breast cancer deaths according to type and presence of comorbidities
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be associated with tumour progression [13]; however, these 
agents were not routinely used in women having chemo-
therapy in this cohort and the chemotherapy rate itself was 
low. Chemotherapy use was not included in the proportional 
hazards regression as it was not significant in the univariate 
analysis comparing the renal and other comorbidity groups.
Smoking causes reno-vascular disease and many types 
of cancer but is only weakly associated with breast cancer 
[14] and poorer breast cancer specific survival [15]; thus, 
previous postulated causation of smoking is unlikely to be 
an important mechanism in this instance. We did not have 
access to smoking history in our cohort.
Despite the poor breast cancer specific survival in the 
renal comorbidity group, it should be remembered that 
twice as many patients died from non-breast cancer causes 
during follow-up. This is in comparison with a 4:1 ratio of 
non-breast cancer deaths to breast cancer deaths in the other 
comorbidity group. It is therefore important that potential 
treatment toxicity issues with systemic therapy are taken 
seriously in all patients with comorbidities.
Weaknesses of the study include it being from a single 
centre and that despite the initial large cohort size, the num-
ber of breast cancer deaths in women with impaired renal 
function is modest. The study looked only at baseline renal 
function which of course changes over time. This study did 
not look at proteinuria as this was not routinely available in 
this cohort. The strength of this study lies in attempting to 
ascertain whether tumour and patient factors contribute to 
or are solely responsible for the poor breast cancer survival 
in women with impaired renal function.
Conclusions
The poor breast cancer specific survival in women with 
impaired renal function is partially explained by advanced 
tumour stage at presentation. However impaired renal func-
tion maintains an independent poor prognostic effect even 
when tumour factors and patient age are taken into account.
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Table 2  Tumour and patient characteristics of the renal and other 
comorbidity groups
Renal Other None Renal vs other
Pre-op nodal mets 23 (21) 21 (12) 151 (18) P = 0.02
Grade 1 8 (7) 22 (12) 109 (13) P = 0.49
Grade 2 66 (62) 101 (55) 455 (53)
Grade 3 33 (31) 59 (32) 288 (34)
Us size < 15 33 (31) 80 (44) 393 (46) P = 0.027
P = 0.006 on 
continuous 
data
Us size > or equal 15 74 (69) 102 (56) 459 (54)
ER pos 89 (83) 152 (84) 714 (84) P = 1
Er neg 18 (17) 30 (16) 138 (16)
Her 2 pos 12 (12) 16 (9) 109 (14) P = 0.48
Her 2 neg 91 (88) 161 (91) 733 (86)
Screen detected 24 (22) 62 (34) 347 (41) P = 0.037
Mean age 75.4 69.0 59.8 P < 0.0001
Chemo 14 (13) 35 (19) 317 (37) P = 0.17
Mean stiffness at SWE 140 120 130 P = 0.004
Total 107 182 852
Table 3  Cox proportional 
hazards regression for breast 
cancer death in women with 
renal and other comorbidities
Covariate b SE Wald P Exp (b) 95% CI of Exp (b)
Age 0.01531 0.01646 0.8654 0.3522 1.0154 0.9832–1.0487
Stiffness 0.0004727 0.003075 0.02363 0.8778 1.0005 0.9945–1.0065
Us_size 0.03746 0.01970 3.6153 0.0572 1.0382 0.9988–1.0790
Preop_nodal_mets 1.4398 0.3874 13.8104 0.0002 4.2196 1.9747–9.0169
Renal impairment 0.8425 0.3972 4.4985 0.0339 2.3221 1.0660–5.0583
Source 1.0830 0.5679 3.6365 0.0565 2.9536 0.9703–8.9907
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Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
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